AstraZeneca today marks a key milestone in its successful move to Cambridge, UK, with the ‘topping out’ of its new, state-of-the-art, strategic R&D centre and global corporate headquarters at the heart of the Cambridge Biomedical Campus (CBC). The Company, including its biologics research and development arm, MedImmune, already has 2,000 employees actively engaged in the city’s vibrant scientific, academic, clinical and business community. Occupation of the site will begin in stages in 2018.
{iframe}https://www.medimmune.com/about-us/media/astrazeneca-and-medimmune-mark-a-key-milestone-with-the-topping-out-of-new-global-r-and-d-centre-in-cambridge-uk-25042017.html{/iframe}